ACLS Study Guide 2015

**Bulletin:** New resuscitation science and American Heart Association treatment guidelines were released October 28, 2015!

The new AHA Handbook of Emergency Cardiac Care (ECC) contains these 2015 Guidelines and is required study for this course. The 2015 ACLS Provider Manual is not yet available. This study guide will provide you with additional study information.

**Website:** [www.heart.org/eccstudent](http://www.heart.org/eccstudent)  **Password:** ACLS15 (Pretest, Videos and ACLS Supplemental Information)
[www.phsinstitute.com](http://www.phsinstitute.com) (study info. For class for rhythm review and ACLS Supplemental Information)

**What is required to successfully complete ACLS?**

For ACLS RENEWALS ONLY: You must successfully score 84% on an ECG rhythm test. This includes naming the rhythm and two causes and two treatments. This information can be found in the ACLS Manual and Supplemental Information.

- Completed ACLS Pre-test is required for admission to the course.
- Score 84% on the multiple-choice post-test.
  - It is a timed test and you may be allowed to use your ECC Handbook.
- You must be able to demonstrate:
  - the ACLS rapid cardiopulmonary assessment
  - using an AED
  - safe defibrillation with a manual defibrillator
  - maintaining an open airway
  - confirmation of effective ventilation
  - addressing vascular access
  - stating rhythm appropriate drugs, route and dose
  - consideration of treatable causes

**What happens if I do not do well in the course?**

The Course Director or Instructor will first “remEDIATE” (tutor) you and you may be allowed to continue in the course. If it is decided you need more time to study, you will be placed into the next course.

**Where do I start?**

- CPR/AED: You will be tested with no coaching. If you cannot perform these skills well without coaching, you can/may be directed to take the course at another time. Know p. 7-11 of this study guide well.
- Arrhythmias: Before you come be sure you can identify: Sinus Rhythm (SR), Sinus Bradycardia (SB), Sinus Tachycardia (ST), Supraventricular Tachycardia (SVT), Ventricular Tachycardia (VT), Ventricular Fibrillation (VF), Torsades de Pointes, Pulseless Electrical Activity (PEA) and Asystole, Atrial Fibrillation, Atrial Flutter, Junctional rhythm, 1st degree Atrial Ventricular Block(1st Degree AVB), 2nd Degree AVB type I (Mobitz I or Wenckebach)/ 2nd Degree AVB, 2nd degree Type II AVB (Mobitz II), 3rd Degree Heart Block and more
You will need to know:

Treat Possible Causes

<table>
<thead>
<tr>
<th>5 Hs</th>
<th>5 Ts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoxia</td>
<td>Amponade</td>
</tr>
<tr>
<td>Hypovolemia</td>
<td>Tension pneumothorax</td>
</tr>
<tr>
<td>Hyper-thermia</td>
<td>Toxins – poisons, drugs</td>
</tr>
<tr>
<td>Hypo/hyperkalemia</td>
<td>Thrombosis – coronary (AMI)</td>
</tr>
<tr>
<td>Hydrogen ion (acidosis)</td>
<td>Thrombosis – pulmonary (PE)</td>
</tr>
</tbody>
</table>

Spacing separations may help as a memory aid.

Rapid Cardiopulmonary Assessment and Algorithms

This is a systematic head-to-toe assessment used to identify in respiratory distress and failure, shock and pulseless arrest. Algorithms are “menus” that guide you through recommended treatment interventions.

Know the following assessment because it begins all ACLS case scenarios. The information you gather during the assessment will determine which algorithm you choose for the patient’s treatment. After each intervention you will reassess the patient again using the head-to-toe assessment.

< Start with general appearance:

Is the level of consciousness:  
A = awake  V = responds to verbal  P = responds to pain  U = unresponsive

< Then assess CABs: (stop and give immediate support when needed, then continue with assessment)

Circulation: Is central pulse present or absent?  
Is the rate normal or too slow or too fast?  
Is the rhythm regular or irregular?  
Is the QRS narrow or wide?

Airway: Check Airway if patient can maintain / if not Open and hold with head tilt-chin lift

Breathing: Is it present or absent?  
Is the rate normal or too slow or too fast?  
Is the pattern regular or irregular or gasping?  
Is the depth normal or shallow or deep?  
Is it Noisy  
is there stridor or wheezing?
<Next look at perfusion:

Is the central pulse versus peripheral pulse strength equal or unequal?

<And check:

BP acceptable or hypotensive?

<Now classify the physiologic status:

Stable: needs little support; reasseess frequently
Unstable: needs immediate support and intervention

<Apply the appropriate treatment algorithm:

• Bradycardia with a Pulse
• Tachycardia with Adequate Perfusion
• Tachycardia with Poor Perfusion
• Pulseless Arrest: VF/VT and Asystole/PEA

Advanced Airway

A cuffed Endotracheal Tube (ET).

Immediately confirm tube placement by clinical assessment and a device:

►Clinical assessment:
• Look for bilateral chest rise.
• Listen for breath sounds over stomach and the 4 lung fields (left and right anterior and midaxillary).
• Look for water vapor in the tube (if seen this is helpful but not definitive).

►Devices:
• End-Tidal CO2 Detector (ETD):
  - Attaches between the ET and Ambu bag; give 6 breaths with the Ambu bag:
    - Litmus paper center should change color with each inhalation and each exhalation.
    - Original color on inhalation = Okay O2 is being inhaled: expected.
    - Color change on exhalation = CO2!! Tube is in trachea.
    - Original color on exhalation = Oh-OH!! Litmus paper is wet: replace ETD.
      Tube is not in trachea: remove ET.
      Cardiac output is low during CPR.

• Esophageal Detector (EDD):
  Resembles a turkey baster:
  - Compress the bulb and attach to end of ET.
  - Bulb inflates quickly! Tube is in the trachea.
- Bulb inflates poorly? Tube is in the esophagus.

f No recommendation for its use in cardiac arrest.

► When sudden deterioration of an intubated patient occurs, immediately check:

D - Displaced = tube is not in trachea or has moved into a bronchus (right mainstem most common)
O - Obstruction = consider secretion or kinking of the tube
P - Pneumothorax = consider chest trauma or barotraumas or non-compliant lung disease
E - Equipment = check oxygen source and Ambu bag and ventilator

**Supraventricular Tachyarrhythmia** The recommended initial biphasic energy dose for cardioversion of atrial fibrillation is 120 to 200 J. The initial monophasic dose for cardioversion of atrial fibrillation is 200 J.

2015 (New) There is inadequate evidence to support the routine use of lidocaine after cardiac arrest. However, the initiation or continuation of lidocaine may be considered immediately after ROSC from cardiac arrest due to VF/pVT.

While earlier studies showed an association between giving lidocaine after myocardial infarction and increased mortality, a recent study of lidocaine in cardiac arrest survivors showed a decrease in the incidence of recurrent VF/pVT but did not show either long-term benefit or harm.

For ease of placement and education, the anterior-lateral pad position is a reasonable default electrode placement. Any of 3 alternative pad positions (anterior-posterior, anterior-left infrascapular, and anterior-right infrascapular) may be considered on the basis of individual patient characteristics.

Placement of AED electrode pads on the victim’s bare chest in any of the 4 pad positions is reasonable for defibrillation.

2015 Continuous quantitative waveform capnography

is now recommended for intubated patients throughout the periarrest period. When quantitative waveform capnography is used for adults, applications now include recommendations for confirming tracheal tube placement and for monitoring CPR quality and detecting ROSC based on end-tidal carbon dioxide.

Capnography to monitor effectiveness of resuscitation efforts. PETCO2 should read 35 to 40 mm Hg in individual of ROSC, High Quality CPR is confirmed by a Capnography read of >10 mm Hg on the vertical axis over time. This patient is intubated and receiving CPR. Note that the ventilation rate is approximately 8 to 10 breaths per minute. Chest compressions are given continuously at a rate of slightly faster than 100/min but are not visible with this tracing.
**In Arrest:**

**Epinephrine:** catecholamine  
ECC Handbook

Increases heart rate, peripheral vascular resistance and cardiac output; during CPR increases myocardial and cerebral blood flow.

- IV/IO: 1 mg of 1:10 000 solution (10ml of 1:10 000) repeat q. 3–5 min
- IV Infusion 2 to 10 mcg/minute
- IV Infusion 0.1 to 0.5 mcg/kg/minute (ROSC)

**Antiarrhythmics:**

**Amiodarone:** atrial and ventricular antiarrhythmic  
ECC Handbook

Slows AV nodal and ventricular conduction, increases the QT interval and may cause vasodilation.

- VF/PVT: IV/IO: 300 mg bolus
- Perfuising VT: IV/IO: 150 mg over 10 min
- IV Infusion: IV/IO: 1 mg/min first 6 hours
- Max: 450 mg
- Caution: hypotension, Torsade; half-life is up to 40 days

**Lidocaine:** ventricular antiarrhythmic to consider when amiodarone is unavailable  
ECC Handbook

Decreases ventricular automaticity, conduction and repolarization.

- VF/PVT: IV/IO: 1 – 1.5 mg/kg bolus first dose, then 0.5 to 0.75 mg/kg, maximum 3 doses or 3mg/kg
- Perfuising VT: IV/IO: 1 – 1.5 mg/kg bolus
- Infusion: 20-50 mcg/kg/min
- Caution: neuro toxicity → seizures

**Magnesium:** ventricular antiarrhythmic for Torsade and hypomagnesemia  
ECC Handbook

Shortens ventricular depolarization and repolarization (decreases the QT interval).

- IV/IO: 1 - 2 g
- Max: 2 gm
- Caution: hypotension, bradycardia

**Increase heart rate:**

**Atropine:** vagolytic to consider after oxygen, ventilation and Fluid Bolus  
ECC Handbook

Blocks vagal input therefore increases SA node activity and improves AV conduction.

- IV/IO: 0.5 mg: may double amount for second dose
- Max: 1mg for AV Block (First Degree, Second Degree Type I)
- 3 mg
- Caution: do not give less than 0.1 mg or may worsen the bradycardia

Atropine is not recommended for routine use in

the management of PEA/asystole and has been removed from

the ACLS Cardiac Arrest Algorithm. The treatment of PEA/
asystole is now consistent in the ACLS
**Decrease heart rate:**

**Adenosine:** drug of choice for symptomatic SVT & Wide Complex Monomorphic VT

Blocks AV node conduction for a few seconds to interrupt AV node re-entry.

- IV/IO: first dose: max: 6 mg
- second dose: max: 12 mg
- Third dose: max: 12 mg

**Adenosine is recommended** in the initial diagnosis and treatment of stable, undifferentiated regular, monomorphic wide-complex tachycardia

**Increase blood pressure:**

**Dobutamine:** synthetic catecholamine

Increases force of contraction and heart rate; causes mild peripheral dilation; may be used to treat shock.

- IV/IO infusion: 2-20 mcg/kg/min infusion
- Caution: tachycardia

**Dopamine:** catecholamine

May be used to treat shock; effects are dose dependent.

- Low dose: increases force of contraction and cardiac output.
- Moderate: increases peripheral vascular resistance, BP and cardiac output.
- High dose: higher increase in peripheral vascular resistance, BP, cardiac work and oxygen demand.

- IV/IO infusion: 2–20 mcg/kg/min
- Caution: tachycardia
- IV/IO infusion: 5–10 mcg/kg/min (ROSC)

**Miscellaneous:**

**Glucose:**

Increases blood glucose in hypoglycemia; prevents hypoglycemia when insulin is used to treat hyperkalemia.

**Naloxone:** opiate antagonist

Reverses respiratory depression effects of narcotics.

- IV/IO: 0.4 to 2 mg/dose IV/IM/subcutaneously. May repeat every 2 to 3 minutes

- Caution: half-life is usually less than the half-life of narcotic, so repeat dosing is often required; ET dose can be given but is not preferred; can also give IM or SQ.

**Sodium bicarbonate:** pH buffer for prolonged arrest, hyperkalemia, tricyclic overdose

- IV/IO: Increases blood pH helping to correct metabolic acidosis.

Moderate metabolic acidosis: 50 to 150 mEq sodium bicarbonate diluted in 1 L of D5W to be intravenously infused at a rate of 1 to 1.5 L/hour during the first hour.

Severe metabolic acidosis: 90 to 180 mEq sodium bicarbonate diluted in 1 L of D5W to be intravenously infused at a rate of 1 to 1.5 L/hour during the first hour.

If acid-base status is not available, dosages should be calculated as follows: 2 to 5 mEq/kg IV infusion over 4 to 8 hours; subsequent doses should be based on patient's acid-base status.

- Caution: causes other drugs to precipitate so flush IV tubing before and after

**ET drug administration:** distribution is unpredictable as is the resulting blood level of the drug; if there is no IV/IO access, give the drug down the ET and flush with 5-10 mL NS then give 5 ventilations to disperse the drug.
Adult Bradycardia With a Pulse Algorithm

1. Assess appropriateness for clinical condition. Heart rate typically <50/min if bradyarrhythmia.

2. Identify and treat underlying cause
   - Maintain patent airway; assist breathing as necessary
   - Oxygen (if hypoxic)
   - Cardiac monitor to identify rhythm; monitor blood pressure and oximetry
   - IV access
   - 12-Lead ECG if available; don’t delay therapy

3. Persistent bradyarrhythmia causing:
   - Hypotension?
   - Acutely altered mental status?
   - Signs of shock?
   - Ischemic chest discomfort?
   - Acute heart failure?

4. Monitor and observe
   - No

5. Atropine
   - If atropine ineffective:
     - Transcutaneous pacing
     - Dopamine infusion
     - Epinephrine infusion

6. Consider:
   - Expert consultation
   - Transvenous pacing

Doses/Details

Atropine IV dose:
First dose: 0.5 mg bolus. Repeat every 3-5 minutes. Maximum: 3 mg.

Dopamine IV infusion:
Usual infusion rate is 2-20 mcg/kg per minute. Titrate to patient response; taper slowly.

Epinephrine IV infusion:
2-10 mcg per minute infusion. Titrate to patient response.

© 2015 American Heart Association
**Adult Tachycardia With a Pulse Algorithm**

1. Assess appropriateness for clinical condition. Heart rate typically ≥150/min if tachyarrhythmia.

2. Identify and treat underlying cause
   - Maintain patent airway; assist breathing as necessary
   - Oxygen (if hypoxemic)
   - Cardiac monitor to identify rhythm; monitor blood pressure and oximetry

3. Persistent tachyarrhythmia causing:
   - Hypotension?
   - Acutely altered mental status?
   - Signs of shock?
   - Ischemic chest discomfort?
   - Acute heart failure?

4. Synchronized cardioversion
   - Consider sedation
   - If regular narrow complex, consider adenosine

5. Wide QRS? ≥0.12 second
   - Yes
   - IV access and 12-lead ECG if available
   - Consider adenosine only if regular and monomorphic
   - Consider antiarrhythmic infusion
   - Consider expert consultation
   - No

6. Yes
   - Synchronized cardioversion
   - Consider sedation
   - If regular narrow complex, consider adenosine

7. No
   - IV access and 12-lead ECG if available
   - Vagal maneuvers
   - Adenosine (if regular)
   - β-Blocker or calcium channel blocker
   - Consider expert consultation

**Doses/Details**

**Synchronized cardioversion:**
Initial recommended doses:
- Narrow regular: 50-100 J
- Narrow irregular: 120-200 J biphasic or 200 J monophasic
- Wide regular: 100 J
- Wide irregular: defibrillation dose (not synchronized)

**Adenosine IV dose:**
First dose: 6 mg rapid IV push; follow with NS flush. Second dose: 12 mg if required.

**Antiarrhythmic Infusions for Stable Wide-QRS Tachycardia**

**Procainamide IV dose:**
20-50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases >50%, or maximum dose 17 mg/kg given. Maintenance infusion: 1-4 mg/min. Avoid if prolonged QT or CHF.

**Amiodarone IV dose:**
First dose: 150 mg over 10 minutes. Repeat as needed if VT recurs. Follow by maintenance infusion of 1 mg/min for first 6 hours.

**Sotalol IV dose:**
100 mg (1.5 mg/kg) over 5 minutes. Avoid if prolonged QT.

© 2015 American Heart Association
Adult Cardiac Arrest Algorithm—2015 Update

1. Start CPR
   - Give oxygen
   - Attach monitor/defibrillator

2. Yes
   - VF/pVT

3. No
   - Asystole/PEA

4. CPR 2 min
   - IV/Io access

5. Yes
   - Shock

6. CPR 2 min
   - Epinephrine every 3-5 min
   - Consider advanced airway, capnography

7. Yes
   - Shock

8. CPR 2 min
   - Amiodarone
   - Treat reversible causes

9. No
   - Asystole/PEA

10. CPR 2 min
    - IV/Io access
    - Epinephrine every 3-5 min
    - Consider advanced airway, capnography

11. Yes
    - Shock

12. CPR 2 min
    - Treat reversible causes

- If no signs of return of spontaneous circulation (ROSC), go to 10 or 11
- If ROSC, go to Post-Cardiac Arrest Care

CPR Quality
- Push hard (at least 2 inches [5 cm]) and fast (100-120/min) and allow complete chest recoil
- Minimize interruptions in compressions
- Avoid excessive ventilation
- Rotate compressor every 2 minutes, or sooner if fatigued
- If no advanced airway, 3:2 compression-ventilation ratio
- Quantitative waveform capnography
  - If $\text{PETCO}_2 < 10 \text{ mm Hg}$, attempt to improve CPR quality
  - Intra-arterial pressure
  - If relaxation phase (diastolic) pressure $< 20 \text{ mm Hg}$, attempt to improve CPR quality

Shock Energy for Defibrillation
- Biphasic: Manufacturer recommendation (eg, initial dose of 120-200 J); if unknown, use maximum available. Second and subsequent doses should be equivalent, and higher doses may be considered
- Monophasic: 360 J

Drug Therapy
- Epinephrine IV/Io dose: 1 mg every 3-5 minutes
- Amiodarone IV/Io dose: First dose: 300 mg bolus. Second dose: 150 mg

Advanced Airway
- Endotracheal intubation or supraglottic advanced airway
- Waveform capnography or capnometry to confirm and monitor ET tube placement
- Once advanced airway in place, give 1 breath every 6 seconds (10 breaths/min) with continuous chest compressions

Return of Spontaneous Circulation (ROSC)
- Pulse and blood pressure
- Abrupt sustained increase in $\text{PETCO}_2$ (typically $> 40 \text{ mm Hg}$)
- Spontaneous arterial pressure waves with intra-arterial monitoring

Reversible Causes
- Hypovolemia
- Hypoxia
- Hypermetabolism
- Hypothermia
- Hypothermia
- Tension pneumothorax
- Tamponade, cardiac
- Toxins
- Thrombosis, pulmonary
- Thrombosis, coronary

© 2015 American Heart Association
Adult Immediate Post–Cardiac Arrest Care Algorithm—2015 Update

1. Return of spontaneous circulation (ROSC)

2. Optimize ventilation and oxygenation
   - Maintain oxygen saturation ≥94%
   - Consider advanced airway and waveform capnography
   - Do not hyperventilate

3. Treat hypotension (SBP <90 mm Hg)
   - IV/IO bolus
   - Vasopressor infusion
   - Consider treatable causes

4. 12-Lead ECG: STEMI OR high suspicion of AMI

5. Coronary reperfusion (Yes)

6. Follow commands? (No)

7. Initiate targeted temperature management (No)

8. Advanced critical care (Yes)

Doses/Details

Ventilation/oxygenation:
Avoid excessive ventilation. Start at 10 breaths/min and titrate to target $\text{PETCO}_2$ of 35-40 mm Hg. When feasible, titrate $\text{FiO}_2$ to minimum necessary to achieve $\text{Spo}_2$ ≥94%.

IV bolus:
Approximately 1-2 L normal saline or lactated Ringer’s

Epinephrine IV infusion:
0.1-0.5 mcg/kg per minute (in 70-kg adult: 7-35 mcg per minute)

Dopamine IV infusion:
5-10 mcg/kg per minute

Norepinephrine
IV infusion:
0.1-0.5 mcg/kg per minute (in 70-kg adult: 7-35 mcg per minute)

Reversible Causes

- Hypovolemia
- Hypoxia
- Hydrogen ion (acidosis)
- Hypo-/hyperkalemia
- Hypothermia
- Tension pneumothorax
- Tamponade, cardiac
- Toxins
- Thrombosis, pulmonary
- Thrombosis, coronary
Acute Coronary Syndromes Algorithm—2015 Update

1. Symptoms suggestive of ischemia or infarction

2. EMS assessment and care and hospital preparation:
   - Monitor, support ABCs. Be prepared to provide CPR and defibrillation
   - Administer aspirin and consider oxygen, nitroglycerin, and morphine if needed
   - Obtain 12-lead ECG; if ST elevation:
     - Notify receiving hospital with transmission or interpretation; note time of onset and first medical contact
   - Notified hospital should mobilize hospital resources to respond to STEMI
   - If considering prehospital fibrinolysis, use fibrinolytic checklist

3. Concurrent ED assessment (<10 minutes)
   - Check vital signs; evaluate oxygen saturation
   - Establish IV access
   - Perform brief, targeted history, physical exam
   - Review/complete fibrinolytic checklist; check contraindications
   - Obtain initial cardiac marker levels, initial electrolyte and coagulation studies
   - Obtain portable chest x-ray (<30 minutes)
   - Immediate ED general treatment
     - If O₂ sat <90%, start oxygen at 4 L/min, titrate
     - Aspirin 160 to 325 mg (if not given by EMS)
     - Nitroglycerin sublingual or spray
     - Morphine IV if discomfort not relieved by nitroglycerin

4. ECG interpretation

5. ST elevation or new or presumably new LBBB; strongly suspicious for injury
   - ST-elevation MI (STEMI)
     - Start adjunctive therapies as indicated
     - Do not delay reperfusion

6. Time from onset of symptoms ≤12 hours?

7. >12 hours

8. ≤12 hours
   - Reperfusion goals:
     - Therapy defined by patient and center criteria
     - Door-to-balloon inflation (PCI) goal of 90 minutes
     - Door-to-needle (fibrinolysis) goal of 30 minutes

9. ST depression or dynamic T-wave inversion; strongly suspicious for ischemia
   - High-risk non-ST-elevation ACS (NSTEMI)
     - Troponin elevated or high-risk patient
     - Consider early invasive strategy if:
       - Refractory ischemic chest discomfort
       - Recurrent/persistent ST deviation
       - Ventricular tachycardia
       - Hemodynamic instability
       - Signs of heart failure
     - Start adjunctive therapies (eg, nitroglycerin, heparin) as indicated

10. Normal or nondiagnostic changes in ST segment or T wave
    - Low-/Intermediate-risk ACS

11. Consider admission to ED chest pain unit or to appropriate bed for further monitoring and possible intervention.
Figure 6

Opioid-Associated Life-Threatening Emergency (Adult) Algorithm—New 2015

Assess and activate.
Check for unresponsiveness and call for nearby help. Send someone to call 9-1-1 and get AED and naloxone. Observe for breathing vs no breathing or only gasping.

Begin CPR.
If victim is unresponsive with no breathing or only gasping, begin CPR.*
If alone, perform CPR for about 2 minutes before leaving to phone 9-1-1 and get naloxone and AED.

Administer naloxone.
Give naloxone as soon as it is available. 2 mg intranasal or 0.4 mg intramuscular. May repeat after 4 minutes.

Does the person respond?
At any time, does the person move purposefully, breathe regularly, moan, or otherwise respond?

Yes
Stimulate and reassess.
Continue to check responsiveness and breathing until advanced help arrives.
If the person stops responding, begin CPR and repeat naloxone.

No
Continue CPR and use AED as soon as it is available.
Continue until the person responds or until advanced help arrives.

* CPR technique based on rescuer’s level of training.

arrest, the provision of naloxone may help an unresponsive patient with severe respiratory depression who only appears to be in cardiac arrest (i.e., it is difficult to determine if a pulse is present).

Intravenous Lipid Emulsion

2015 (Updated): It may be reasonable to administer ILE, concomitant with standard resuscitative care, to patients who have premonitory neurotoxicity or cardiac arrest due to local anesthetic toxicity. It may be reasonable to administer ILE to patients with other forms of drug toxicity who are failing standard resuscitative measures.

2010 (Old): It may be reasonable to consider ILE for local anesthetic toxicity.

Why: Since 2010, published animal studies and human case reports have examined the use of ILE for patients with drug toxicity that is not the result of local anesthetic infusion. Although the results of these studies and reports
Positions for 6-Person High-Performance Teams

Resuscitation Triangle Roles

**Compressor**
- Assesses the patient
- Does 5 cycles of chest compressions
- Alternates with AED/Monitor/Defibrillator every 5 cycles or 2 minutes (or earlier if signs of fatigue set in)

**AED/Monitor/Defibrillator**
- Brings and operates the AED/monitor/defibrillator
- Alternates with Compressor every 5 cycles or 2 minutes (or earlier if signs of fatigue set in), ideally during rhythm analysis
- If a monitor is present, places it in a position where it can be seen by the Team Leader (and most of the team)

**Airway**
- Opens and maintains the airway
- Provides ventilation

The team owns the code. No team member leaves the triangle except to protect his or her safety.

Leadership Roles

**Team Leader**
- Every resuscitation team must have a defined leader
- Assigns roles to team members
- Makes treatment decisions
- Provides feedback to the rest of the team as needed
- Assumes responsibility for roles not assigned

**Administer Medications**
- An ALS provider role
- Administers medications

**Timer/Recorder**
- Records the time of interventions and medications (and announces when these are next due)
- Records the frequency and duration of interruptions in compressions
- Communicates these to the Team Leader (and the rest of the team)

*This is a suggested team formation. Roles may be adapted to local protocol.*

© 2016 American Heart Association
ECG REVIEW

1

Rhythm **SINUS TACH**

2

a. Rhythm Sinus Rhythm
3

Rhythm SVT

4

a. Rhythm: Atrial Flutter

5

a. Rhythm: Sinus Brady
Rhythm: Atrial Fibrillation (No regular Ps, variable rate and fibrillatory baseline)

Rhythm: Junctional Rhythm. ~ 60 bpm

Rhythm: Monomorphic V-Tach
Rhythm: Sinus Rhythm W/ multifocal PVC’s

Rhythm: Sinus Rhythm W/ PVC
Rhythm: Polymorphic V-Tach (Probably normal QT)

a. Rhythm: 2nd Degree type II

Rhythm: Fine V-Fib
a. Rhythm: 1 Degree AVB

Rhythm: Coarse V-Fib

Rhythm: Sinus Rhythm W/PAC
Rhythm: 2nd Degree type I

Rhythm: Polymorphic V-Tach / Torsades de Points

Rhythm: Asystole
Rhythm: 3rd Degree
## How to use the H’s and T’s.
### THE H’s and T’s – POTENTIALLY REVERSIBLE CAUSES
You must use these on all cardiac arrests and near cardiac arrests.

<table>
<thead>
<tr>
<th>H’s</th>
<th>T’s</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypovolemia</strong> (is this pt hypovolemic?)</td>
<td><strong>Tablets</strong> (drug OD, accidents)</td>
</tr>
<tr>
<td>1. Look for obvious fluid/blood loss.</td>
<td>2. Support circulation while you find an antidote or</td>
</tr>
<tr>
<td>2. Secure IO/IV access</td>
<td>Reversal drug- (Poison control)</td>
</tr>
<tr>
<td>3. Give fluid boluses and reassess</td>
<td>2. If no drug OD suspected, move on to the next T. Check mark for tablets</td>
</tr>
<tr>
<td>4. Check mark for Hypovolemia</td>
<td><strong>Tamponade</strong> (cardiac)</td>
</tr>
<tr>
<td><strong>Hypoxia</strong> (is this person hypoxic?)</td>
<td><strong>Tension pneumothorax</strong></td>
</tr>
<tr>
<td>1. Confirm chest rise and bilateral breath sounds with each ventilation</td>
<td><strong>Thrombosis, coronary (ACS)</strong></td>
</tr>
<tr>
<td>2. Check O₂ source (trace from bag to flow meter)</td>
<td><strong>Thrombosis, pulmonary (embolism)</strong></td>
</tr>
<tr>
<td>3. Check mark for hypoxia</td>
<td><strong>Trauma</strong></td>
</tr>
<tr>
<td><strong>Hydrogen Ion Acidosis</strong> (is this pt acidic?) (Respiratory or metabolic)</td>
<td>Tablets (drug OD, accidents)</td>
</tr>
<tr>
<td>1. Respiratory acidosis ensure adequate ventilation (don’t hyperventilate!)</td>
<td>1. Support circulation while you find an antidote or</td>
</tr>
<tr>
<td>2. Metabolic acidosis give sodium bicarbonate</td>
<td>Reversal drug- (Poison control)</td>
</tr>
<tr>
<td>3. Check mark for acidosis</td>
<td>2. If no drug OD suspected, move on to the next T. Check mark for tablets</td>
</tr>
<tr>
<td><strong>Hyper/Hypokalemia</strong> (is there any evidence hyper/hypokalemia in this pt?)</td>
<td><strong>Tamponade</strong> (chest trauma, chest malignancy, recent central line insertion, JVD, narrow pulse pressure, electrical alternans etc...)</td>
</tr>
<tr>
<td>1. For elevated S-T’s and tall peaked T waves (hyperkalemia) give calcium chloride 10ml of 10% over 5 minutes</td>
<td>1. <strong>Pericardial centesis</strong></td>
</tr>
<tr>
<td>2. Hypokalemia, (Flat T-waves &amp; U waves ) give potassium 20 to 30 meq/hour, Magnesium 1 to 2 g (2 to 4 ml of 50% solution) diluted in 10 ml of D5W IV/IO</td>
<td>If no history or ruled out move on to the next T and check mark for Tamponade</td>
</tr>
<tr>
<td>4. If no signs of hyper/hypokalemia move to the next H.</td>
<td><strong>Tension Pneumothorax</strong> (chest asymmetry, tympani, diminished breath sounds, high peak pressures, JVD, tracheal deviation, severe respiratory distress etc...)</td>
</tr>
<tr>
<td>5. Checkmark for hyper/hypokalemia</td>
<td>1. Vent tension in chest</td>
</tr>
<tr>
<td><strong>Hyper/Hypothermia</strong> (take a temp)</td>
<td>2. Support ventilation and oxygenation with BVM and intubate as necessary</td>
</tr>
<tr>
<td>1. If too hot, cool down</td>
<td>3. If no history or ruled out move on to the next T and check mark for pneumothorax</td>
</tr>
<tr>
<td>2. If too cold, warm up</td>
<td><strong>Thrombosis (coronary or pulmonary)</strong></td>
</tr>
<tr>
<td>3. If normothermic or mildly hypothermic go to the next H.</td>
<td>1. Consider fibrinolysis for suspected coronary or pulmonary embolus.</td>
</tr>
<tr>
<td>4. Check mark for Hyper/hypothermia</td>
<td>2. CPR is not an absolute contraindication for fibrinolysis.</td>
</tr>
<tr>
<td><strong>Hypo/Hyperglycemia</strong></td>
<td>3. If no history or ruled out move on to the next T and check mark for thrombosis</td>
</tr>
<tr>
<td>1. Accu-check and correct if needed.</td>
<td><strong>Trauma</strong></td>
</tr>
<tr>
<td>2. If normoglycemic move to the T’s Checkmark for Hvdo/hyperglycemia</td>
<td>inspect body completely.</td>
</tr>
<tr>
<td><strong>Trauma</strong></td>
<td>Remove all clothes.</td>
</tr>
</tbody>
</table>

By Terry White Oct 2012
ADENOSINE
indications for use
*First drug for most forms of stable narrow complex SVT.
*Effective in terminating those due to reentry involving AV node or sinus node.

AMIODARONE
indications for use
*VF/pulseless VT unresponsive to shock delivery, CPR, and a vasopressor.
*Recurrent, hemodynamically unstable VT

ATROPINE SULFATE
indications for use
*First drug for symptomatic bradycardia
*May be beneficial in presence of AV nodal block
*Organophosphate poisoning

DOPAMINE
indications for use
*Second line drug for symptomatic bradycardia
*For hypotension with signs and symptoms of shock

EPINEPHRINE
indications for use
*Cardiac arrest: VF, pulseless VT, asystole, PEA
*Symptomatic bradycardia
*Severe hypotension
*Anaphylaxis, severe allergic reactions

LIDOCAINE
indications for use
*Alternative to amiodarone in cardiac arrest from VF/VT
*Stable monophasic VT with preserved ventricular function
*Stable polymorphic VT with normal baseline QT interval & preserves LV function
*Stable polymorphic VT with baseline QT-interval prolongation if torsades suspected

MAGNESIUM SULFATE
indications for use
*For use in cardiac arrest only if torsades-de-pointes or suspected hypomagnesemia present
*Life threatening ventricular arrhythmias due to digitalis toxicity
Vasopressors for Resuscitation: Epinephrine

It may be reasonable to administer epinephrine as soon as feasible after the onset of cardiac arrest due to an initial nonshockable rhythm. A very large observational study of cardiac arrest with nonshockable rhythm compared epinephrine given at 1 to 3 minutes with epinephrine given at 3 later time intervals (4 to 6, 7 to 9, and greater than 9 minutes). The study found an association between early administration of epinephrine and increased ROSC, survival to hospital discharge, and neurologically intact survival.

Key Words:

2 Introduction - Updated

These Web-based Integrated Guidelines incorporate the relevant recommendations from 2010 and the new or updated recommendations from 2015. Basic life support (BLS), advanced cardiovascular life support (ACLS), and post–cardiac arrest care are labels of convenience that each describe a set of skills and knowledge that are applied sequentially during the treatment of patients who have a cardiac arrest. There is overlap as each stage of care progresses to the next, but generally ACLS comprises the level of care between BLS and post–cardiac arrest care.

ACLS training is recommended for advanced providers of both prehospital and in-hospital medical care. In the past, much of the data regarding resuscitation was gathered from out-of-hospital arrests, but in recent years, data have also been collected from in-hospital arrests, allowing for a comparison of cardiac arrest and resuscitation in these 2 settings. While there are many similarities, there are also some differences between in- and out-of-hospital cardiac arrest etiology, which may lead to changes in recommended resuscitation treatment or in sequencing of care. The consideration of steroid administration for in-hospital cardiac arrest (IHCA) versus out-of-hospital cardiac arrest (OHCA) is one such example discussed in this Part.

The recommendations in this 2015 American Heart Association (AHA) Guidelines Update for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) are based on an extensive evidence review process that was begun by the International Liaison Committee on Resuscitation (ILCOR) after the publication of the ILCOR 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
In this in-depth evidence review process, the ILCOR task forces examined topics and then generated prioritized lists of questions for systematic review. Questions were first formulated in PICO (population, intervention, comparator, outcome) format, and then a search strategy and inclusion and exclusion criteria were defined and a search for relevant articles was performed. The evidence was evaluated by using the standardized methodological approach proposed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group.

The quality of the evidence was categorized based on the study methodologies and the 5 core GRADE domains of risk of bias, inconsistency, indirectness, imprecision, and other considerations (including publication bias). Then, where possible, consensus-based treatment recommendations were created.

To create the 2015 Guidelines Update, the AHA formed 15 writing groups, with careful attention to avoid or manage conflicts of interest, to assess the ILCOR treatment recommendations and to write AHA treatment recommendations by using the AHA Class of Recommendation and Level of Evidence (LOE) system.

The recommendations made in this 2015 Guidelines Update are informed by the ILCOR recommendations and GRADE classification, in the context of the delivery of medical care in North America. The AHA ACLS writing group made new recommendations only on topics specifically reviewed by ILCOR in 2015. This chapter delineates any instances where the AHA writing group developed recommendations that are substantially different than the ILCOR statements. In the online version of this document, live links are provided so the reader can connect directly to the systematic reviews on the Scientific Evidence Evaluation and Review System (SEERS) website. These links are indicated by a superscript combination of letters and numbers (eg, ALS 433). This update uses the newest AHA COR and LOE classification system, which contains modifications of the Class III recommendation and introduces LOE B-R (randomized studies) and B-NR (nonrandomized studies) as well as LOE C-LD (limited data) and LOE C-EO (consensus of expert opinion). All recommendations made in this 2015 Guidelines Update, as well as in the 2010 Guidelines, are listed in the Appendix. For further information, see "Part 2: Evidence Evaluation and Management of Conflicts of Interest." The ILCOR ACLS Task Force addressed 37 PICO questions related to ACLS care (presented in this Part) in 2015. These questions included oxygen dose during CPR, advanced airway devices, ventilation rate during CPR, exhaled carbon dioxide (CO2 ) detection for confirmation of airway placement, physiologic monitoring during CPR, prognostication during CPR, defibrillation, antiarrhythmic drugs, and vasopressors. The 2 new topics are steroids and hormones in cardiac arrest, and extracorporeal CPR (ECPR), perhaps better known to the inpatient provider community as extracorporeal life support (ECMO). The 2010 Guidelines Part on electrical therapies (defibrillation and emergency pacing) has been eliminated, and relevant material from it is now included in this ACLS Part. The major changes in the 2015 ACLS guidelines include recommendations about prognostication during CPR based on exhaled CO2 measurements, timing of epinephrine administration stratified by shockable or nonshockable rhythms, and the possibility of bundling treatment of steroids, vasopressin, and epinephrine for treatment of in-hospital arrests. In addition, the administration of vasopressin as the sole vasoactive drug during CPR has been removed from the algorithm.

3 Adjuncts to CPR - Updated
3.1 Oxygen Dose During CPR - Updated ALS 889

The 2015 ILCOR systematic review considered inhaled oxygen delivery both during CPR and in the post–cardiac arrest period. This 2015 Guidelines Update evaluates the optimal inspired concentration of oxygen during CPR. The immediate goals of CPR are to restore the energy state of the heart so it can resume mechanical work and to maintain the energy state of the brain to minimize ischemic injury. Adequate oxygen delivery is necessary to achieve these goals. Oxygen delivery is dependent on both blood flow and arterial oxygen content. Because